CD38 and plasma cell myeloma: However, we also reported a possible off-target effect of daratumumab which result in depletion of other CD38 expressing regulatory cells including Treg, Breg, MDSC etc. This feature makes daratumumab attractive for multiple myeloma (122), but could trigger alloimmune responses in transplantation patients.